Data from multiple sources - Curated by EPG Health - Last updated 06 June 2017
Cystic fibrosis (CF) is an autosomal recessive, life-limiting, genetically inherited disease. It is a multi-system disorder and results from one of several identified...
Added 6 days ago Drug news
Vertex Pharmaceuticals Incorporated announced that the FDA approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis...
Added 17 days ago Drug news
VX 659 and VX 445 enter phase III trials as triple therapies to treat cystic fibrosis withF508del gene mutation.
Added 1 month ago Drug news
EU approval for Orkambi to treat cystic fibrosis (F508del mutation) in children ages 6 through 11.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
Specialised CF care has led to a dramatic improvement in survival in CF: in the last four decades, well above...
Added 3 years ago
This review summarizes state-of-the art culture methods and makes recommendations for addition of non-culture based methods in the diagnostic laboratory.
Added 4 years ago
Inert gas washout tests, performed using the single- or multiple-breath washout technique, were first described over 60 years ago. As...
Added 5 years ago
Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.
Background: To determine in vivo effects of CFTR modulators on mutation S945L.
Added 24 days ago
Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
The CFTR potentiator, ivacaftor (IVA), has been widely used in the treatment of cystic fibrosis (CF) patients with the G551D mutation. To date, there has been limited information on the microbiological status...
Added 24 days ago
- Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- Registration required
- Subscription fee